# US 2021/0198233 A1 · Thiophene derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198233 A1
- Document ID: US20210198233A1
- Status: Published application
- Kind: A1
- Application number: 17/250,059
- Filed: 2019-05-15
- Published: 2021-07-01
- Earliest claimed: 2018-05-18
- Assignees: Merck Patent GmbH; Ryvu Therapeutics S.A.
- Applicants: Merck Patent GmbH; Ryvu Therapeutics S.A.
- Inventors: Matthias Leiendecker; Hans-Peter Buchstaller
- Web page: https://patentgrep.com/patent/US20210198233A1

## CPC

- C07D 333/78: condensed with rings other than six-membered or with ring systems containing such rings
- A61K 31/381: having five-membered rings
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4436: containing a heterocyclic ring having sulfur as a ring hetero atom
- A61P 35/00: Antineoplastic agents
- C07D 333/72: Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 495/06: Peri-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of the formula I in which R1 denotes A, Ar, Cyc, Het, COA or CN, R2 denotes SO2A, SOA, SA, SO2NHA, SO2NA2, S(═NH,═O)A, S(═NH)2A, NO2, Hal, CN, A, Het1, COOH or COOA, R3 denotes H or Hal, R4 denotes H or Hal, n denotes 1, 2 or 3, A denotes unbranched or branched alkyl having 1-6 C-atoms, Cyc denotes cyclic alkyl with 3 to 7 C-atoms, Ar denotes phenyl, Het denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, Het1 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, and Hal denotes F, Cl, Br, or I, are inhibitors of HIF-2α, and can be employed for the treatment of diseases such as cancer.

## Claims

### Claim at position 1

1: A compound of the formula I:
in which
R1 denotes A, Ar, Cyc, Het, COA, or CN,
R2 denotes SO2A, SOA, SA, SO2NHA, SO2NA2, S(═NH,═O)A, S(═NH)2A, NO2, Hal, CN, A, Het1, COOH, or COOA,
R3 denotes H or Hal,
R4 denotes H or Hal,
A denotes unbranched or branched alkyl having 1-6 C-atoms, in which 1-7 H atoms may be replaced by OH, F, Cl, and/or Br, and/or in which one or two non-adjacent CH2 groups may be replaced by O and/or NH groups,
Cyc denotes cyclic alkyl with 3, 4, 5, 6, or 7 C-atoms,
Ar denotes phenyl, which is unsubstituted or mono-, di-, or trisubstituted by Hal, A, [C(R5)2]pOR5, O[C(R5)2]pOR5, [C(R5)2]pN(R5)2, O[C(R5)2]pN(R5)2, [C(R5)2]pHet1, NO2, CN, [C(R5)2]pCOOR5, O[C(R5)2]pCOOR5, CON(R5)2, NR5COA, NR5SO2A, SO2N(R5)2, S(O)2A, COHet1, O[C(R5)2]pHet1, NHCOOA, NHCON(R5)2, NHCOO[C(R5)2]mN(R5)2, NHCOO[C(R5)2]pHet1, NHCONH[C(R5)2]mN(R5)2, NHCONH[C(R5)2]pHet1, OCONH[C(R5)2]mN(R5)2, OCONH[C(R5)2]pHet1, S(O)2Het1, and/or COA,
Het denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, which may be unsubstituted or mono-, di-, or trisubstituted by Hal, A, NH2, NHA, NA2, COOH, COOA, CONH2, CONHA, CONA2, CONHAr, S(O)mA, NHCH2Ar1, CN, OH, and/or OA,
Het1 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, which may be unsubstituted or mono-, di-, or trisubstituted by Hal, A, COOA, NH2, NHA, and/or NA2,
Ar1 denotes phenyl which is unsubstituted or mono-, di-, or trisubstituted by Hal, A, OH, and/or OA,
R5 denotes H or alkyl with 1, 2, 3 or 4 C-atoms,
Hal denotes F, Cl, Br, or I,
n denotes 1, 2, or 3,
m denotes 1, 2, or 3,
p denotes 0, 1, 2, 3, or 4,
and pharmaceutically acceptable salts, tautomers, and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim at position 2 (depends on 1)

2: The compound according to claim 1, in which:
R1 denotes Ar or Het,
and pharmaceutically acceptable solvates, salts, tautomers, and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim at position 3 (depends on 1)

3: The compound according to claim 1, in which:
R2 denotes SO2A,
and pharmaceutically acceptable salts, tautomers, and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim at position 4 (depends on 1)

4: The compound according to claim 1, in which:
R3 denotes H or F,
R4 denotes H or F,
and pharmaceutically acceptable salts, tautomers, and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim at position 5 (depends on 1)

5: The compound according to claim 1, in which:
A denotes unbranched or branched alkyl having 1-6 C-atoms, in which 1-5 H atoms may be replaced by OH and/or F,
and pharmaceutically acceptable salts, tautomers, and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim at position 6 (depends on 1)

6: The compound according to claim 1, in which:
Ar denotes phenyl, which is unsubstituted or mono-, di-, or trisubstituted by Hal and/or CN,
and pharmaceutically acceptable salts, tautomers, and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim at position 7 (depends on 1)

7: The compound according to claim 1, in which:
Het denotes a monocyclic aromatic heterocycle having 1 to 4 N, O, and/or S atoms, which may be unsubstituted or mono-, di-, or trisubstituted by Hal, A, CN, OH, and/or OA,
and pharmaceutically acceptable salts, tautomers, and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim at position 8 (depends on 1)

8: The compound according to claim 1, in which:
Het denotes pyrrolyl, pyrazolyl, imidazolyl, pyridinyl, or pyrimidinyl, each of which may be unsubstituted or mono-, di- or trisubstituted by Hal, OA, OH, A, and/or CN,
and pharmaceutically acceptable salts, tautomers, and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim at position 9 (depends on 1)

9: The compound according to claim 1, in which:
R1 denotes Ar or Het,
R2 denotes SO2A,
R3 denotes H or Hal,
R4 denotes H or Hal,
A denotes unbranched or branched alkyl having 1-6 C-atoms, in which 1-5 H atoms may be replaced by OH and/or F,
Ar denotes phenyl, which is unsubstituted or mono-, di-, or trisubstituted by Hal and/or CN,
Het denotes a monocyclic aromatic heterocycle having 1 to 4 N, O, and/or S atoms, which may be unsubstituted or mono-, di-, or trisubstituted by Hal, A, CN, OH, and/or OA,
Hal denotes F, Cl, Br, or I,
n denotes 1, 2, or 3,
and pharmaceutically acceptable salts, tautomers, and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim at position 10 (depends on 1)

10: The compound according to claim 1, selected from the the following:
No.
Structure
13a
(4S)-1-(3-chloro-5-fluorophenyl)-5,5-difluoro-3-methanesulfonyl-
4H,6H-cyclopenta[c]thiophen-4-ol
23a
(S)-1-(3,5-difluorophenyl)-5,5-difluoro-3-methanesulfonyl-4,5,6,7-
tetrahydro-2-benzothiophen-4-ol
25a
(4S)-5,5-difluoro-3-methanesulfonyl-1-phenyl-4H,6H-
cyclopenta[c]thiophen-4-ol
26a
(4S)-1-(3,5-difluorophenyl)-5,5-difluoro-3-methanesulfonyl-4H,6H-
cyclopenta[c]thiophen-4-ol
27a
(4S)-5,5-difluoro-1-(2-fluorophenyl)-3-methanesulfonyl-
4H,6H-cyclopenta[c]thiophen-4-ol
28a
(4S)-5,5-difluoro-1-(3-fluorophenyl)-3-methanesulfonyl-4H,6H-
cyclopenta[c]thiophen-4-ol
29a
(4S)-5,5-difluoro-1-(4-fluorophenyl)-3-methanesulfonyl-4H,6H-
cyclopenta[c]thiophen-4-ol
30a
(4S)-1-(3,4-difluorophenyl)-5,5-difluoro-3-methanesulfonyl-4H,6H-
cyclopenta[c]thiophen-4-ol
31a
4-[(4S)-5,5-difluoro-4-hydroxy-3-methanesulfonyl-4H,6H-
yclopenta[c]thiophen-1-yl]-2-fluorobenzonitrile
32a
3-[(4S)-5,5-difluoro-4-hydroxy-3-methanesulfonyl-4H,6H-
cyclopenta[c]thiophen-1-yl]benzonitrile
33a
3-[(4S)-5,5-difluoro-4-hydroxy-3-methanesulfonyl-4H,6H-
cyclopenta[c]thiophen-1-yl]-5-fluorobenzonitrile
34a
(4S)-3-chloro-5-[(4S)-5,5-difluoro-4-hydroxy-3-methanesulfonyl-
4H,6H-cyclopenta[c]thiophen-1-yl]benzonitrile
35a
(4S)-5,5-difluoro-3-methanesulfonyl-1-(1-methyl-1H-pyrazol-4-yl)-
4H,5H,6H-cyclopenta[c]thiophen-4-ol
36a
(4R)-3-methanesulfonyl-1-phenyl-4,5,6,7-tetrahydro-2-
benzothiophen-4-ol
37a
(4S)-5,5-difluoro-1-(3-fluorophenyl)-3-methanesulfonyl-6,7-dihydro-
4H-2-benzothiophen-4-ol
38a
(4S)-5,5-difluoro-1-(4-fluorophenyl)-3-methanesulfonyl-6,7-dihydro-
4H-2-benzothiophen-4-ol
39a
(4S)-1-(1,3-dimethyl-1H-pyrazol-4-yl)-5,5-difluoro-3-
methanesulfonyl-4,5,6,7-tetrahydro-2-benzothiophen-4-ol
40a
(4S)-5,5-difluoro-3-methanesulfonyl-1-(1-methyl-1H-pyrazol-4-yl)-
4,5,6,7-tetrahydro-2-benzothiophen-4-ol
41a
(4S)-1-(3,4-difluorophenyl)-5,5-difluoro-3-methanesulfonyl-4,5,6,7-
tetrahydro-2-benzothiophen-4-ol
42a
3-[(4S)-5,5-difluoro-4-hydroxy-3-methanesulfonyl-4,5,6,7-tetrahydro-
2-benzothiophen-1-yl]-5-fluorobenzonitrile
43a
4-[(4S)-5,5-difluoro-4-hydroxy-3-methanesulfonyl-4,5,6,7-
tetrahydro-2-benzothiophen-1-yl]-1-methyl-1H-pyrrole-2-carbonitrile
44a
4-[(4S)-5,5-difluoro-4-hydroxy-3-methanesulfonyl-4,5,6,7-
tetrahydro-2-benzothiophen-1-yl]-1-methyl-1H-pyrrole-2-carbonitrile
45a
(4S)-1-(3-chloro-5-fluorophenyl)-5,5-difluoro-3-
methanesulfonyl-4,5,6,7-tetrahydro-2-benzothiophen-4-ol
46a
(4S)-5,5-difluoro-3-methanesulfonyl-1-[1-methyl-3-(trifluoromethyl)-
1H-pyrazol-5-yl]-4,5,6,7-tetrahydro-2-benzothiophen-4-ol
47a
(4S)-5,5-difluoro-3-methanesulfonyl-1-(1-methyl-1H-pyrazol-5-yl)-
4H,5H,6H-cyclopenta[c]thiophen-4-ol
48a
(4S)-5,5-difluoro-3-methanesulfonyl-1-[1-methyl-3-(trifluoromethyl)-
1H-pyrazol-5-yl]-4H,5H,6H-cyclopenta[c]thiophen-4-ol
49a
(4S)-1-(1,3-dimethyl-1H-pyrazol-5-yl)-5,5-difluoro-3-
methanesulfonyl-4H,5H,6H-cyclopenta[c]thiophen-4-ol
50a
(4S)-1-(1,3-dimethyl-1H-pyrazol-5-yl)-5,5-difluoro-3-
methanesulfonyl-4,5,6,7-tetrahydro-2-benzothiophen-4-ol
51a
5-[(4S)-5,5-difluoro-4-hydroxy-3-methanesulfonyl-4,5,6,7-tetrahydro-
2-benzothiophen-1-yl]-1-methyl-1H-pyrazole-3-carbonitrile
52a
3-[(4S)-5,5-difluoro-4-hydroxy-3-methanesulfonyl-4,5,6,7-tetrahydro-
2-benzothiophen-1-yl]-1-methyl-1H-pyrazole-4-carbonitrile
53a
4-[(4S)-5,5-difluoro-4-hydroxy-3-methanesulfonyl-4,5,6,7-tetrahydro-
2-benzothiophen-1-yl]-1-methyl-1H-pyrazole-3-carbonitrile
54a
3-[(4S)-5,5-difluoro-4-hydroxy-3-methanesulfonyl-4,5,6,7-tetrahydro-
2-benzothiophen-1-yl]-1-methyl-1H-pyrazole-5-carbonitrile
55a
(4S)-1-(2,6-difluoropyridin-4-yl)-5,5-difluoro-3-methanesulfonyl-
4,5,6,7-tetrahydro-2-benzothiophen-4-ol
56a
(4S)-1-(5-chloropyridin-3-yl)-5,5-difluoro-3-methanesulfonyl-4,5,6,7-
tetrahydro-2-benzothiophen-4-ol
57a
(4S)-5,5-difluoro-3-methanesulfonyl-1-(5-methylpyridin-3-yl)-4,5,6,7-
tetrahydro-2-benzothiophen-4-ol
58a
(4S)-5,5-difluoro-1-(5-fluoropyridin-3-yl)-3-methanesulfonyl-4,5,6,7-
tetrahydro-2-benzothiophen-4-ol
59a
5-[(4S)-5,5-difluoro-4-hydroxy-3-methanesulfonyl-4,5,6,7-tetrahydro-
2-benzothiophen-1-yl]pyridine-3-carbonitrile
60a
6-[(4S)-5,5-difluoro-4-hydroxy-3-methanesulfonyl-4,5,6,7-tetrahydro-
2-benzothiophen-1-yl]-4-methylpyridine-2-carbonitrile
61a
(4S)-1-(6-chloro-5-fluoropyridin-3-yl)-5,5-difluoro-3-
methanesulfonyl-4,5,6,7-tetrahydro-2-benzothiophen-4-ol
62a
(4S)-5,5-difluoro-3-methanesulfonyl-1-[5-(trifluoromethyl)pyridin-3-
yl]-4,5,6,7-tetrahydro-2-benzothiophen-4-ol
63a
(4S)-1-(2-chloro-6-fluoropyridin-4-yl)-5,5-difluoro-3-
methanesulfonyl-4,5,6,7-tetrahydro-2-benzothiophen-4-ol
64a
6-chloro-4-[(4S)-5,5-difluoro-4-hydroxy-3-methanesulfonyl-4,5,6,7-
tetrahydro-2-benzothiophen-1-yl]pyridine-2-carbonitrile
65a
(4S)-1-(5-chloro-6-methoxypyridin-3-yl)-5,5-difluoro-3-
methanesulfonyl-4,5,6,7-tetrahydro-2-benzothiophen-4-ol
66a
(4S)-5,5-difluoro-1-(3-fluorophenyl)-3-methanesulfonyl-4,5,6,7-
tetrahydro-2-benzothiophen-4-ol
67a
(4S,5S)-1-(3-chloro-5-fluorophenyl)-5-fluoro-3-methanesulfonyl-
4H,5H,6H-cyclopenta[c]thiophen-4-ol
68a
(4S,5R)-1-(3-chloro-5-fluorophenyl)-5-fluoro-3-
methanesulfonyl-4H,5H,6H-cyclopenta[c]thiophen-4-ol
and pharmaceutically acceptable solvates, salts, tautomers, and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim at position 11 (depends on 1)

11: A process for preparation of the compound according to claim 1 and pharmaceutically acceptable salts, solvates, tautomers, and stereoisomers thereof, the process comprising:
a) reacting a compound of the formula II:
in which R2, R3, R4, and n have the meanings indicated in claim 1, and X is F, Cl, Br or I,
with a compound of formula III:
L-R1 III,
in which R1 has the meaning indicated in claim 1,
and L denotes H, a boronic acid or a boronic acid ester group,
or
b) reacting a compound of the formula IV:
in which R1, R2, R3, R4, and n have the meanings indicated in claim 1, with NaBH4,
and/or
converting a base or acid of the formula I into one of the base's or acid's salts.

### Claim at position 12 (depends on 1)

12: A medicament, comprising:
at least one compound according to claim 1 and/or pharmaceutically acceptable salts, solvates, tautomers, and stereoisomers thereof, including mixtures thereof in all ratios, and
optionally a pharmaceutically acceptable carrier, excipient, or vehicle.

### Claim at position 13 (depends on 1)

13: A method for treatment of cancer and von Hippel-Lindau disease, comprising:
administering the compound according to claim 1 and pharmaceutically acceptable salts, solvates, tautomers, and stereoisomers thereof, including mixtures thereof in all ratios, to a patient in need thereof.

### Claim at position 14 (depends on 13)

14: The process according to claim 13, wherein the cancer is selected from the group consisting of cancer of head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, urinary bladder, uterine, cervix, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain, central nervous system, solid tumors, blood-borne tumors, glioblastoma, renal cell carcinoma, and clear cell renal cell carcinoma.

### Claim at position 15 (depends on 1)

15: A medicament, comprising:
at least one compound according to claim 1 and/or pharmaceutically acceptable salts, solvates, and stereoisomers thereof, including mixtures thereof in all ratios, and
at least one further medicament active ingredient.

### Claim at position 16 (depends on 1)

16: A kit, comprising:
(a) a first pack, comprising an effective amount of the compound according to claim 1 and/or pharmaceutically acceptable salts, solvates, salts, and stereoisomers thereof, including mixtures thereof in all ratios, and
(b) a second pack, comprising an effective amount of a further medicament active ingredient.
